Gemcitabine With or Without Docetaxel and Resection for Recurrent Osteosarcoma: The Experience at Children's Memorial Hospital

Gosiengfiao, Y.; Reichek, J.; Woodman, J.; Ben-Ami, T.; Walterhouse, D.

J Pediatr Hematol Oncol. 2012 Jan 6; 34(2):e63-5

Abstract

It remains unclear how to optimally incorporate gemcitabine and docetaxel into the management of patients with recurrent osteosarcoma. We describe 4 pediatric patients with recurrent osteosarcoma who were treated with gemcitabine+/-docetaxel and resection. One patient had a partial response and 2 had stable disease. Two patients subsequently underwent surgical resections. Median duration of response was 8 months and was longer for patients who underwent resection. One patient remains disease-free 57 months from recurrence. Our limited series provides additional support for the use of gemcitabine+/-docetaxel for recurrent osteosarcoma and suggests benefit of concurrent local control measures if possible.

Read More on PubMed